CVS Health Beats The Street; Raises Guidance
CVS Health Beat The Street in its Q1 financial news and raised its full-year projections. Its Aetna insurance division has recovered well from a huge meltdown a few years ago. Revenue should reach at least $405 billion this year. It posed $2.9 billion in profit in Q1. Revenues also grew to $100.4 billion in Q1 2025.
Executives said that while the final 2027 Medicare Advantage (MA) rate notice does not meet financial expectations, Aetna is still on track for planned margin improvements by 2028.
Additional articles: https://www.fiercehealthcare.com/payers/cvs-health-beats-street-29b-q1-profit and https://www.modernhealthcare.com/insurance/mh-aetna-revenue-cvs-health-earnings-outlook/ and https://www.modernhealthcare.com/insurance/mh-cvs-health-earnings-outlook-aetna/ and https://www.beckerspayer.com/financial/cvs-health-reports-2-9b-in-q1-profit-as-aetna-strengthens/
#aetna #cvshealth #margins #medicareadvantage #healthplans
Large Plans Plot Continued Recovery
The largest insurers spent Q1 continuing to navigate tight revenue and operational times. This interesting Becker’s Payer article covers the major focuses: navigating continued Medicare Advantage (MA) funding pressures, a recovering Medicaid financial picture but uncertain times with coming programmatic cuts, continued pressure on prior authorization reforms, and the need for AI investments.
#healthplans #margins #medicareadvantage #obbba #medicaid #exchanges #ai
CMS Fines MA Plans
The Centers for Medicare and Medicaid Services (CMS) has fined 13 health plans a combined $1.5 million for Medicare Advantage (MA) program violations for plan year 2022. Claims processing system errors caused enrollees to pay more for medical services and prescription drugs. In January, the agency fined seven plans nearly $2.5 million for other contract violations.
#medicareadvantage #compliance #cms #audits
BRIDGE Announced For July 1
Starting in July, some obese Medicare beneficiaries could get GLP-1 weight-loss drugs Wegovy, Zepbond, and Foundayo for $50 a month. This is under the temporary BRIDGE program from the Trump administration in the Part D program. The administration wanted to launch a long-term program known as BALANCE in 2027, but too few plans expressed interest given cost unknowns, Instead, BRIDGE will go for 18 months to gather data on costs and member risks. It is hoped that more plans will agree to take risk on such drugs beginning in 2028.
Beneficiaries must be enrolled in a Medicare Part D plan and have a body mass index of 27 or higher and have a condition such as heart disease or prediabetes, among others. People with BMIs of 35 or higher automatically qualify.
About 40% of adults are clinically obese, with a BMI of 30 or higher. Those already on such drugs may also qualify.
Additional article: https://kffhealthnews.org/medicare/cheaper-glp-1-weight-loss-medicare-bridge-wegovy-zepbound-foundayo/
#glp1s #partd #medicareadvantage #pdp #cms #bridge #drugpricing
— Marc S. Ryan
